Ubaka Ogbogu
Ubaka Ogbogu is an Assistant Professor and the Katz Group Research Fellow in Health Law at the Faculty of Law, University of Alberta. His teaching and research interests include health law, law and biotechnology, law and bioethics, science and regulation, and legal history. Ubaka is a former SCN trainee and a recipient of the SCN Canadian Alumni Award. He has done extensive research work on the ethical, legal and social issues associated with stem cell research, and continues to research and publish in this area. Ubaka holds law degrees at the bachelors and masters levels from the University of Benin in Nigeria and the University of Alberta, and is currently in the process of completing a doctorate in law at the University of Toronto. His doctoral work focuses on the legal history of early health care and biotechnology policies in Canada, particularly in relation to smallpox vaccination and infectious diseases.
Posts by: Ubaka
Chris Kamel’s recent post on chemically derived transcription factors for iPS cell production is very exciting for a variety of non-scientific reasons. Most notably, the innovative procedure and future improvements are likely to ease ethical, safety and legal concerns regarding the use of oncogenic transcription factors. One such concern is the possibility that Canadian law […]
The US Court of Appeals in Washington DC yesterday suspended a recent temporary injunction issued by a federal district judge against the use of federal funds for hESC research. Read my earlier post on the injunction. The suspension is temporary, and is intended to allow the appellate court sufficient opportunity to review an emergency appeal […]
On August 23, 2010, United States federal district judge Royce C. Lamberth issued a preliminary injunction that overturned President Obama’s recent reform of US federal policy on human embryonic stem cell (hESC) research. The injunction — which will remain in effect until a permanent order is issued upon final determination of the merits of the […]
The U.K. Government has announced plans to dissolve the Human Fertilisation and Embryology Authority (HFEA) and the Human Tissue Authority (HTA) – two independent regulators primarily responsible for stem cell research oversight in the U.K. – and to transfer their functions to a new yet-to-be-named research regulator. The HFEA was created under the 1990 Human […]
On June 30, the Canadian Institutes of Health Research (CIHR) released updated Guidelines for Human Pluripotent Stem Cell Research. The Guidelines apply to all research involving human pluripotent stem cells conducted with funding from, or under the auspices of institutions receiving funding from the three federal granting agencies, known as the Tri-Council: CIHR, Natural Sciences […]
Comments